Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide

CONTEXT: Diazoxide, the only U.S. Food and Drug Administration–approved drug to treat hyperinsulinemic hypoglycemia, has been associated with several adverse events, which has raised concerns about the safety of this drug. Existing reports are limited to small studies and case reports. OBJECTIVE: To...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Endocrinol Metab
Κύριοι συγγραφείς: Herrera, Adriana, Vajravelu, Mary Ellen, Givler, Stephanie, Mitteer, Lauren, Avitabile, Catherine M, Lord, Katherine, De León, Diva D
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Endocrine Society 2018
Θέματα:
Clinical Research Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207144/
https://ncbi.nlm.nih.gov/pubmed/30247666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-01613
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια